Japanese medical technology specialist ARKRAY set up its first Asian research centre outside of its home country in Singapore.
The new R&D unit will be housed in government research agency Institute of Bioengineering and Nanotechnology (IBN). The company will invest $9.1 million over a five-year period in this research venture and collaboration.
"We have chosen to set up our newest research centre in Singapore because of IBN's distinguished knowledge and expertise in a wide variety of scientific fields, and we believe we can find a lot of opportunities to produce synergy with IBN through a long-term relationship," said Takeshi Matsuda, president and CEO of ARKRAY.
Founded in 1960, ARKRAY is a pioneer in the field of automated analysis systems and is one of the leading makers of diabetes monitoring devices.
ARKRAY's new research centre incubated in IBN will employ 21 researchers and will focus on developing novel detection kits for infectious diseases.
"IBN identifies with ARKRAY's vision of improving lives through scientific advancement and new technological discoveries. We are confident that our collaboration with ARKRAY will lead to new devices and advanced instruments for disease detection and monitoring," said Professor Jackie Y. Ying, executive director of IBN.
IBN specialises in the area of biodevices and diagnostics for early and accurate disease detection. Since it was founded in 2003, IBN has established an active portfolio of over 620 patents/patent applications. It has spun off six companies in the medical technology sector.
Sign up for CIO Asia eNewsletters.